
UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE

SERVICE DE RADIODIAGNOSTIC ET RADIOLOGIE INTERVENTIONNELLE

Chef de service : Professeur Pierre Schnyder

**PERFUSION AND DIFFUSION MRI OF GLIOBLASTOMA PROGRESSION
IN A FOUR-YEAR PROSPECTIVE TEMOZOLOMIDE CLINICAL TRIAL**

THESE

Préparée sous la supervision du Professeur Reto Meuli

et présentée à la Faculté de Biologie et de Médecine
de l'Université de Lausanne pour l'obtention du grade de

DOCTEUR EN MEDECINE

par

ANTOINE LEIMGRUBER

Médecin diplômé de la Confédération Suisse

Originaire de Fribourg FR et Herznach AG

02
380
Le:

BF 7E 3416

Lausanne
2006

IRM DE PERFUSION ET DE DIFFUSION DE LA PROGRESSION DU GLIOBLASTOME DANS UN ESSAI CLINIQUE PROSPECTIF DE 4 ANS DU TEMOZOLOMIDE

RESUME

BUT

Cette étude a été menée sur le suivi de patients traités pour un glioblastome nouvellement diagnostiqué. Son objectif a été de déterminer l'impact des séquences de perfusion et de diffusion en imagerie par résonance magnétique (IRM). Un intérêt particulier a été porté au potentiel de ces nouvelles techniques d'imagerie dans l'anticipation de la progression de la maladie. En effet, l'intervalle de temps libre de progression est une mesure alternative de pronostic fréquemment utilisée.

MATERIEL ET METHODE

L'étude a porté sur 41 patients participant à un essai clinique de phase II de traitement par temozolomide. Leur suivi radiologique a comporté un examen IRM dans les 21 à 28 jours après radiochimiothérapie et tous les 2 mois par la suite. L'évaluation des images s'est faite sur la base de l'évaluation de l'effet de masse ainsi que de la mesure de la taille de la lésion sur les images suivantes : T1 avec produit de contraste, T2, diffusion, perfusion. Afin de déterminer la date de progression de la maladie, les critères classiques de variation de taille adjoints aux critères cliniques habituels ont été utilisés.

RESULTAT

311 examens IRM ont été revus. Au moment de la progression (32 patients), une régression multivariée selon Cox a permis de déterminer deux paramètres de survie : diamètre maximal en T1 ($p > 0.02$) et variation de taille en T2 ($p < 0.05$). L'impact de la perfusion et de la diffusion n'a pas été démontré de manière statistiquement significative.

CONCLUSION

Les techniques de perfusion et de diffusion ne peuvent pas être utilisées pour anticiper la progression tumorale. Alors que la prise de décision au niveau thérapeutique est critique au moment de la progression de la maladie, l'IRM classique en T1 et en T2 reste la méthode d'imagerie de choix. De manière plus spécifique, une prise de contraste en T1 supérieure à 3 cm dans son plus grand diamètre associée à un hypersignal T2 en augmentation forment un marqueur de mauvais pronostic.

CLINICAL INVESTIGATION

PERFUSION AND DIFFUSION MRI OF GLIOBLASTOMA PROGRESSION IN A FOUR-YEAR PROSPECTIVE TEMOZOLOMIDE CLINICAL TRIAL

ANTOINE LEIMGRUBER, M.Sc.,* SANDRINE OSTERMANN, Ph.D.,[†] EUN JO YEON, M.D.,* EVELYN BUFF,*
PHILIPPE P. MAEDER, M.D.,* ROGER STUPP, M.D.,[†] AND RETO A. MEULI, M.D., Ph.D.*

*Department of Radiology, Lausanne State and University Hospital, and [†]Department of Oncology, Multidisciplinary Center for
Oncology, Lausanne State and University Hospital, Lausanne, Switzerland

Purpose: This study was performed to determine the impact of perfusion and diffusion magnetic resonance imaging (MRI) sequences on patients during treatment of newly diagnosed glioblastoma. Special emphasis has been given to these imaging technologies as tools to potentially anticipate disease progression, as progression-free survival is frequently used as a surrogate endpoint.

Methods and Materials: Forty-one patients from a phase II temozolomide clinical trial were included. During follow-up, images were integrated 21 to 28 days after radiochemotherapy and every 2 months thereafter. Assessment of scans included measurement of size of lesion on T1 contrast-enhanced, T2, diffusion, and perfusion images, as well as mass effect. Classical criteria on tumor size variation and clinical parameters were used to set disease progression date.

Results: A total of 311 MRI examinations were reviewed. At disease progression (32 patients), a multivariate Cox regression determined 2 significant survival parameters: T1 largest diameter ($p < 0.02$) and T2 size variation ($p < 0.05$), whereas perfusion and diffusion were not significant.

Conclusion: Perfusion and diffusion techniques cannot be used to anticipate tumor progression. Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard. Specifically, a T1 contrast enhancement over 3 cm in largest diameter together with an increased T2 hypersignal is a marker of inferior prognosis. © 2005 Elsevier Inc.

Magnetic resonance imaging, Perfusion, Diffusion, Glioblastoma, Progression.

INTRODUCTION

Glioblastoma (GBM) is the most frequent primary brain tumor among adults (1, 2). Despite surgery, radiotherapy, and adjuvant chemotherapy (3, 4), this tumor almost invariably recurs at its initial site. Disease progression usually occurs within 3 to 6 months and rapidly leads to death. New treatments for patients with this malignant neoplasm have recently been developed. Among these treatments, temozolomide, an alkylating agent, has shown activity against GBM (5–8). In the phase II trial on which this study is based, we have shown the feasibility and promising survival of the administration of temozolomide chemotherapy with concomitant radiotherapy followed by up to 6 cycles of adjuvant treatment (8). This approach has recently been shown to improve progression-free and overall survival in a randomized phase III trial (9).

In parallel to the recent use of temozolomide, several advanced imaging technologies have become more readily available in cancer centers and hospitals. Thus, the frequent

use of magnetic resonance imaging (MRI) has set standards in the brain imaging of tumors by allowing better topographic diagnosis and delineation of tumor extension. T1 gadolinium-enhanced imaging is used to assess the leakage of contrast agent through the blood–brain barrier, commonly disrupted in high-grade glioma, and T2-weighted imaging is used to estimate edema development. However, because of the inherent difficulty in measuring response to treatment or assessing true disease progression in the brain (10), complementary imaging techniques may be of great clinical significance. MRI diffusion and perfusion imaging—in contrast to more complex and expensive techniques such as PET with amino acid tracers and thallium 201 SPECT—can be used to supplement routine MRI investigations without excessive time and cost increase (11, 12). Furthermore, both diffusion and perfusion imaging techniques can be helpful and potentially superior to T1 and T2 in the management of tumor evolution. For example, diffusion imaging reflects cellularity (13, 14), and perfusion imaging may give information on vascular density and

angiogenesis (15–17). These advanced MRI techniques may improve radiologic prediction of response or progression and thus be helpful for the accurate treatment adjustment for an individual patient.

In this study, we aimed to evaluate and confirm the added value of perfusion and diffusion MRI sequences in patients treated at a single institution within a prospective clinical trial. Thus, evolution of GBM in a homogeneous patient population was carefully monitored by a close medical and radiologic follow-up, with classical T1-weighted and T2-weighted MRI, as well as diffusion and perfusion imaging. This study analyzes in particular the behavior of T2, perfusion, and diffusion at disease progression. Special attention has been given to the use of these imaging technologies as tools to potentially anticipate disease progression. Furthermore, multivariate survival analysis has been carried out to establish which radiologic criteria could be especially useful for neuroradiologists and oncologists who examine MRIs of patients with glioblastoma.

METHODS AND MATERIALS

Patients and therapy

Patients with newly diagnosed and histologically confirmed glioblastoma were enrolled in a prospective phase II clinical trial. Treatment after biopsy or surgery consisted of radiotherapy and concomitant temozolomide during 6 weeks, followed after a 4 week interval by up to 6 monthly cycles of adjuvant temozolomide (8). Among the 64 patients enrolled in this trial, 41 patients treated at a single institution and for whom MRI documentation was available were considered for this radiologic ancillary study. Thirty-five patients (85%) received at least 1 cycle of adjuvant therapy, and 19 patients (46%) received all 6 cycles of adjuvant temozolomide. Twenty-three patients (56%) were male and 26 patients (63%) were at least 50 years of age. Concomitant medication and, in particular, corticosteroid and antiepileptic drugs were carefully recorded.

Imaging and follow-up

Baseline tumor imaging with MRI and CT was performed in our institution and in outside hospitals, and follow-up MRIs were performed solely in our institution. Thus, adequate MRI baseline tumor imaging was available for 28 patients. Subsequently, follow-up included MRI 21 to 28 days after the end of radiochemotherapy and every 2 months thereafter, until disease progression. Progression was usually confirmed with a second MRI after an interval of 4 to 8 weeks but without histologic confirmation. Second surgery for recurrence was usually not recommended. MR examinations were elaborated at 1.5 Tesla. T1-weighted sagittal and T2-weighted transverse spin-echo images were obtained first. Diffusion-weighted images were acquired by application of a spin-echo echoplanar technique in which a diffusion weighted b factor of 1,000 s/mm² in 3 orthogonal directions was used that allowed the computation of trace diffusion-weighted images. Twenty 5-mm thick slices with an interslice gap of 1.5 mm were used to cover the entire brain. Perfusion data were achieved with a gradient-echo echoplanar technique that allowed the acquisition of 10 5-mm thick slices (gap 1.5 mm) in the transverse orientation centered on the lesion. One stack of images was acquired every 1.2

seconds during the first pass of a bolus of contrast agent injected in an antecubital vein through a power injector (0.1 mmol/kg at a rate of 4 mL/s, followed by the injection of 20 mL of saline water at the same injection rate). Postcontrast T1-weighted images in the sagittal and transverse orientation were then obtained.

Perfusion series were processed on commercially available software (Functool; General Electric Medical Systems, Milwaukee, WI). Two different color-coded perfusion maps were produced. The first map was based on the maximum slope of decrease of the MR signal during the first pass of the contrast agent through the brain. The second map displayed the negative-enhancement integral of the MR signal along time during this same first pass. These 2 maps measure the cerebral blood flow (CBF) and the cerebral blood volume (CBV), respectively.

All imaging was acquired over a 40-month period between April 1998 and August 2001. Survival data have been considered up to March 2002, with a median number of MRI examinations per patient of 6 (range, 1–21) and a median follow-up of 15.2 months (range, 5.3–46.5 months).

Image review process

Complete MRI records of each patient from study entry until death or until the cutoff date (August 2001) were prepared for a second reading. Two neuroradiologists who were unaware of the patients' outcome reviewed and scored the images in agreement.

Six categories of radiologic criteria have been scored: localization (lobe and hemisphere), mass effect, T1 contrast enhancement, T2 hypersignal, diffusion hypersignal, and perfusion hypersignal. Mass effect was reported as none, local, moderate midline shift, or severe midline shift. T1 contrast enhancement was described as absent, linear, nodular, or multiple nodular. T2 hypersignal was assigned a morphologic code: none, limited to a lobe, extension to more than a lobe, or contralateral extension. Signs of leucoencephalopathy (diffuse T2 hypersignals that span the white matter, accompanied by shrinkage of overall brain volume) were also recorded. On diffusion-weighted images, the presence or absence of hypersignal was assessed, and perfusion hypersignal was graded on maximum slope of decrease and negative integral enhancement maps.

The images were compared with the previous examination and variations of each criterion graded as increased, stable, or decreased. T1 contrast enhancement sizes were measured in millimeters, by use of largest diameter and orthogonal diameter (18). T2, diffusion, and perfusion hypersignals were measured in the same way. Mass-effect variation was graded according to the evolution of 3 classical criteria: sulcus and cisterns vanishing, ventricles shift and deformation, and median line shift.

Disease progression

Disease progression was assessed by the tumor size variation on T1 contrast enhancement and clinical parameters according to the Macdonald criteria (19). An increase greater than or equal to 25% in size, an increase in corticosteroid consumption, or a deteriorating neurologic function was defined as disease progression.

Time reference

For the purpose of this paper, the images acquired at the time of disease progression are designated t_0 , a reference in time used to monitor the disease's evolution. The behavior of T2, mass effect, perfusion, and diffusion imaging at t_0 , but also at the previous (t_{-1})

and at the following MRI examination (t_{+1}), were compared with the classical WHO criteria and to the Macdonald criteria (18, 19).

Statistics

Overall survival was evaluated from study entry to death or censored on March 15, 2002, according to the Kaplan-Meier method (20).

Univariate analyses were conducted as a step toward multivariate analysis. Patients at t_0 were segregated in 2 groups, according to a criterion such as T1 largest diameter, T2 hypersignal, mass effect, surgery vs. biopsy, or age. A log-rank test was performed to compare the survival curves of the 2 groups. A p value less than or equal to 0.05 was considered significant.

Significant criteria for survival established by univariate analyses were used in a multivariate Cox model of proportional hazards (21). Criteria were included one at a time in the model, from the lowest log-rank p value to the highest. A p value less than or equal to 0.05 was considered significant.

RESULTS

Patients, tumor location, and imaging

A total of 311 MRI examinations from 41 patients were reviewed. The 41 patients included in this radiologic ancillary study are representative of the whole study population with regard to demographics, progression-free survival, and overall survival (data not shown) (8). Adequate MRI baseline tumor imaging was available for 28 patients. Perfusion and diffusion data were available in 71% (220 examinations) and 77% (240 examinations), respectively.

Most tumors had an extension in the frontal lobe (46%) compared with the temporal or parietal lobes (25%). In 3 patients (7%), the tumor was located in the occipital lobe, whereas in 6 patients (15%), a bilateral butterfly-like tumor extension was present. Some tumors (7%) extended deeper into the central region of the brain.

Time to disease progression and survival

At the time of completion of the review process, a total of 32 patients (78%) had demonstrated disease progression on the basis of radiologic and clinical signs. At the first examination with disease progression (t_0), 22 out of the 32 patients (69%) were still in treatment (4-week intervals or adjuvant). Progression-free survival was computed at 6.9 months (95% CI, 5.3 to 8.5 months). Overall survival was 15.7 months (95% CI, 14.3 to 17 months), survival after progression was 6.6 months (95% CI, 4.6 to 8.6 months).

T1 contrast enhancement and T2 hypersignal

At disease progression, we noted nodular contrast enhancement in all patients. Twenty-two out of the 28 patients with postoperative baseline MR imaging available presented also a nodular contrast enhancement at baseline, and 4 patients presented a linear and 2 patients presented no contrast enhancement.

During the follow-up, T2-weighted imaging of the 41 patients showed 2 different patterns of evolution. The hypersignal was often focalized in the vicinity of the lesion

Table 1. Summary of findings at postoperative baseline and at disease progression

	Mass effect											
	No midline shift			Midline shift			T1 contrast enhancement			T2 hypersignal		
	None	Local	Moderate	Moderate	Severe	None	Linear	Nodular	None	1 Lobe	> 1 Lobe	Contralateral
Postoperative baseline ($n = 28$)	25% ($n = 7$)	39% ($n = 11$)	36% ($n = 10$)	—	—	7% ($n = 2$)	14% ($n = 4$)	79% ($n = 22$)	7% ($n = 2$)	54% ($n = 15$)	21% ($n = 6$)	18% ($n = 5$)
Disease progression (t_0) ($n = 32$)	28% ($n = 9$)	47% ($n = 15$)	22% ($n = 7$)	3% ($n = 1$)	—	—	—	100% ($n = 32$)	—	31% ($n = 10$)	38% ($n = 12$)	31% ($n = 10$)

The value of n is the number of examinations available; the percent sign (%) indicates percent of examinations available.

Table 2. Variation of radiological parameters at different follow-up times

Parameter	Variation	Follow-up time		
		t_{-1}	t_0	t_{+1}
T1 contrast enhancement	Increase	0%	100% ($n = 32$)	57% ($n = 12$)
	Stable	64% ($n = 16$)	0%	33% ($n = 7$)
	Decrease	36% ($n = 9$)	0%	10% ($n = 2$)
T2 hypersignal	Increase	16% ($n = 4$)	63% ($n = 20$)	64% ($n = 14$)
	Stable	68% ($n = 17$)	28% ($n = 9$)	32% ($n = 7$)
	Decrease	16% ($n = 4$)	9% ($n = 3$)	4% ($n = 1$)
Mass effect	Increase	0%	37.5% ($n = 12$)	45.5% ($n = 10$)
	Stable	76% ($n = 19$)	50% ($n = 16$)	45.5% ($n = 10$)
	Decrease	24% ($n = 6$)	12.5% ($n = 4$)	9% ($n = 2$)
Perfusion	Increase	0%	40% ($n = 8$)	25% ($n = 4$)
	Stable	66% ($n = 10$)	55% ($n = 11$)	69% ($n = 11$)
	Decrease	33% ($n = 5$)	5% ($n = 1$)	6% ($n = 1$)
Diffusion	Increase	0%	54% ($n = 13$)	39% ($n = 7$)
	Stable	69% ($n = 11$)	42% ($n = 10$)	50% ($n = 9$)
	Decrease	31% ($n = 5$)	4% ($n = 1$)	11% ($n = 2$)

Follow-up time t_0 is the first examination graded as disease progression; t_{-1} and t_{+1} examinations following t_0 . The percent sign (%) indicates percent of the available examinations. The value of n is the number of available examinations; n at t_{-1} is smaller than n at t_0 because an examination before t_{-1} is not always available to evaluate the variation at t_{-1} .

and showed an alteration caused by the tumor. By contrast, 9 patients in this cohort showed leucoencephalopathy signs (overall brain volume shrinkage accompanied by a hyperintense T2 signal that spanned the white matter). These patients had a median survival time of 26.7 months (95% CI, 6.9 to 46.5 months). Leucoencephalopathy is a known late complication in patients treated for malignant glioma and occurs 18 to 24 months after radiotherapy. Table 1 offers a summary of the findings and scores at postoperative baseline and at disease progression.

Signs of disease progression

The first examination with disease progression (t_0) was monitored in comparison with its preceding (t_{-1}) and following (t_{+1}) examinations. Five main radiologic parameters were monitored: T1 contrast enhancement, T2 hypersignal, mass effect, perfusion hypersignal, and diffusion hypersignals. At t_0 , all patients demonstrated an increase in T1 contrast enhancement. At examination t_{-1} , no parameter presented a clear variation that predicted this progression. Specifically, no perfusion and diffusion image could anticipate disease progression. Both perfusion postprocessing methods on cerebral blood flow (CBF) and cerebral blood volume (CBV) led to the same conclusion in 203 out of 220 examinations.

Of the other parameters, only T2 hypersignal showed a clear tendency to increase at t_0 , which thus suggests disease progression. On an MRI performed 2 months after first progression (t_{+1}), the delayed tendency of the parameters to increase was confirmed. (Table 2, Fig. 1).

Warning signs at disease progression

At t_0 , univariate log-rank analysis was completed to identify potential prognostic factors for a multivariate model.

Each radiologic parameter and the clinical prognostic factors age, performance status, and debulking surgery (8) have been analyzed for survival. Size of T1 contrast enhancement, variation of T2 hypersignal and of mass effect, debulking surgery, and age were retained in this order for the multivariate model (Table 3).

The multivariate analysis used a Cox model. It was performed in an ascending manner; that is by addition of 1 parameter from Table 3 at a time. Only 2 parameters, namely, largest diameter of T1 contrast enhancement and variation in T2 hypersignal, remained statistically significant in the analysis ($p < 0.05$) (Table 4). Because this




Fig. 1. Potential markers of disease progression increase from first follow-up examination to time t_{-1} , t_0 , or t_{+1} . White indicates perfusion hypersignal. Light gray indicates diffusion hypersignal. Gray indicates mass effect. Dark gray indicates T2 hypersignal. Black indicates T1 contrast enhancement. Values are displayed in percent of the examinations available, as an examination before t_{-1} is not always available to evaluate the variation at t_{-1} . Abbreviations: t_0 , first examination graded as disease progression; t_{-1} , t_{+1} , examination preceding and following, respectively, after t_0 .

Table 3. Univariate log-rank survival analysis

Grouping parameter*	<i>p</i> Value at t_0	Median survival in months (95% CI)	Median progression-free survival in months (95% CI)
T1 largest diameter			
≥ 3 cm	<0.001 (<i>n</i> = 16 vs. 16)	13.6 (6.3–20.9)	6.1 (4.3–7.9)
<3 cm		26.8 (14.6–39.0)	8.7 (0–20.7)
T2 hypersignal			
Increase	<0.005 (<i>n</i> = 21 vs. 11)	14.3 (10.4–18.2)	6.3 (5.7–6.9)
No increase		42.7 (30.7–54.7)	18.2 (0–39.6)
Mass effect			
Increase	<0.02 (<i>n</i> = 12 vs. 20)	8.8 (5.3–12.3)	6.3 (5.7–6.9)
No increase		17.1 (6.5–27.7)	18.2 (0–39.6)
Debulking surgery			
Full or partial	<0.02 (<i>n</i> = 25 vs. 7)	16.7 (16.1–17.3)	8.7 (8.5–8.9)
None		10.6 (3.0–18.2)	5.5 (4.3–6.7)
Age at diagnostic			
≥ 50 y	<0.05 (<i>n</i> = 21 vs. 11)	12.1 (5.2–19.0)	6.1 (5.3–6.9)
<50 y		26.8 (10.7–42.9)	13.7 (7.4–20.0)

Follow-up time t_0 is the first examination graded as disease progression.

* Each grouping parameter splits the patients in two subsets. Survival of the first subset was tested against the survival of the second subset. The two values of *n* are the number of patients in each two subsets.

analysis identified only 2 parameters as significant, an overall score at disease progression could not be proposed. However, at first progression (t_0), the subset of 14 patients with a T1 contrast enhancement largest diameter above 3 cm in size and simultaneously a T2 hypersignal that increased since last examination (t_{-1}) had a median survival of 13.6 months (95% CI, 5.8 to 21.4 months) compared with a median survival of 28.2 months (95% CI, 10.8 to 45.6 months) for the other 18 patients. This difference in survival time was significant (log-rank $p < 0.001$), which demonstrated that these 2 parameters are crucial radiologic warning signs at progression.

DISCUSSION

Over the past 10 years, MRI has become the principal imaging modality on which clinicians base the follow-up and the evaluation of brain tumors. MRI and assessment of clinical parameters such as neurologic function and corticosteroid use are integral parts of the widely used Macdonald's response criteria for primary brain tumors (19). However, some specific aspects of the follow-up, such as response assessment and tumor-specific imaging, increasingly challenge radiologists (22). Delayed morphologic

changes caused by treatment and contrast uptake on blood-brain barrier disruption after surgery or radiotherapy are difficulties that may obscure the picture. For these reasons, additional imaging techniques may be of help (22). In specific situations, positron emission tomography (PET) that use amino acids tracers and ^{201}Tl single-photon emission computed tomography (SPECT) have demonstrated additional value for the imaging of brain tumors (11, 12). These techniques are nonetheless far from being commonly available in health centers, and performing an additional examination is a burden to the patients and the health-care system.

Recent works have shown the potential of perfusion and diffusion imaging in assessment of tumor development. Histologic changes such as angiogenesis are evaluated by perfusion and cellularity is evaluated by diffusion imaging (13, 15–17). We assessed in a group of 41 homogeneously treated patients with glioblastoma (GBM) whether these techniques would allow us to anticipate disease progression. In particular, for the evaluation of new treatment or new chemotherapy agents, progression-free survival is frequently used as a surrogate endpoint (23). To our knowledge, few reports on gliomas specifically focus on Grade IV astrocytoma, and none includes a homogeneous set of patients comparable with ours. In our study, despite careful,

Table 4. Multivariate Cox model (proportional hazards) of survival

Parameter	Follow-up time					
	t_0			t_{+1}		
	<i>p</i> Value	Hazard ratio	95% CI	<i>p</i> Value	Hazard ratio	95% CI
T1 largest diameter	<0.02	5.7	1.5–22	<0.05	3.9	1.0–15
T2 hypersignal	<0.05	3.0	1.0–8.9	<0.05	5.7	1.0–31

Follow-up time t_0 is the first examination graded as disease progression; t_{+1} examination follows t_0 .

onsistent, and frequent (every 2 months) evaluation, we could not show that perfusion and diffusion techniques added valuable information. These 2 techniques did not anticipate disease progression.

Other reports in animal models are consistent with the results of our clinical trial. In effect, on GL261 implanted mouse gliomas, T1 contrast enhancement has been shown to be present before evidence of angiogenesis (17). Thus, blood-brain barrier disruption is not necessarily caused by neovascularization. Furthermore, for GBM in humans, perfusion is not positively correlated with tumor growth. Possibly, the microvasculature of such hypercellular glioma cannot meet the metabolic demands of the growing tumor. Ischemic necrosis is then the logical outcome of this peculiar unstable state (16).

The value of the diffusion technique is subject to much debate. Diffusion hypersignal on diffusion-weighted trace images increases with cellularity (14), whereas it decreases during edema development (24). A consequence of this condition is a rather complex behavior in tumors in which both increased cellularity and increased edema are present. Indeed, as the tumor grows and its cellularity tends to increase, disruption of the blood-brain barrier will lead to edema. These factors then have radiologic effects on diffusion behavior that tend to counteract each other. A recent study on patients with various brain tumors and treatments has shown the potential of diffusion variation to delineate tumor regions that respond to treatment at a very early timepoint during radiation therapy (25). Compared with that study, our work focuses on diffusion variation in relation with disease progression at a longer time scale in a homogeneous population of GBM. In this setting, diffusion variation was not able to anticipate disease progression. In a similar way, the 8 patients with progressive disease of the

Moffat *et al.* (25) study presented only minor changes in ADC. Indeed, because diffusion imaging reflects histopathological changes, further studies should focus on homogenous populations in terms of pathology and treatment. For example, lower-grade gliomas show different histopathological patterns that will lead to other imaging effects, whereas nonenhancing malignancies would certainly benefit on follow-up techniques that do not rely on contrast-enhancement techniques.

Hence, perfusion and diffusion showed a rather complex behavior and did not enable us to foresee disease progression. Classical parameters, thus, remain the imaging reference. A T1 contrast enhancement of over 3 cm in largest diameter together with the increase of T2 hypersignal is proposed as a marker of inferior prognosis. Conventional clinical and radiologic parameters of tumor progression have confirmed their usefulness in our study. Moreover, our MRI follow-up scheme, with simple time course denominations such as t_{-1} , t_0 , and t_{+1} and multivariate analysis, has demonstrated its pertinence and could easily be transposed to other brain tumors and treatments. When used on large cohorts, this statistical approach would certainly lead to the identification of more parameters that could then be brought together in useful prognostic scoring functions.

In conclusion, our work showed that although elaborate imaging techniques such as perfusion and diffusion MRI are becoming standardized in many medical centers, they do not enable the radiologist to anticipate disease progression. Classical T1 imaging remains the gold standard in the follow-up of tumor growth. Together with T2 imaging, this technique is accurate in reflecting the current evolution of the brain tumor. The quest for more precise imaging techniques to monitor biologic effects of treatment for high-grade gliomas continues (22).

REFERENCES

- DeAngelis LM. Brain tumors. *N Engl J Med* 2001;344:114-123.
- Stupp R, Hegi ME. Recent developments in the management of malignant glioma. ASCO 2003 Educational Book. Alexandria; 2003. p. 779-788.
- Burger PC, Vogel FS, Green SB, *et al.* Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. *Cancer* 1985;56:1106-1111.
- Walker MD, Green SB, Byar DP, *et al.* Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. *N Engl J Med* 1980;303:1323-1329.
- Brada M, Hoang-Xuan K, Rampling R, *et al.* Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. *Ann Oncol* 2001;12:259-266.
- Stupp R, Gander M, Leyvraz S, *et al.* Current and future developments in the use of temozolomide for the treatment of brain tumours. *Lancet Oncol* 2001;2:552-560.
- Newlands ES, O'Reilly SM, Glaser MG, *et al.* The Charing Cross Hospital experience with temozolomide in patients with gliomas. *Eur J Cancer* 1996;32A:2236-2241.
- Stupp R, Dietrich PY, Ostermann Kraljevic S, *et al.* Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. *J Clin Oncol* 2002;20:1375-1382.
- Stupp R, Mason WP, van den Bent MJ, *et al.* Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352:987-996.
- Vos MJ, Uitdehaag BM, Barkhof F, *et al.* Interobserver variability in the radiological assessment of response to chemotherapy in glioma. *Neurology* 2003;60:826-830.
- Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. *Semin Nucl Med* 2003;33:148-162.
- Vos MJ, Hoekstra OS, Barkhof F, *et al.* Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. *J Clin Oncol* 2003;21:3559-3565.
- Sugahara T, Korogi Y, Kochi M, *et al.* Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. *J Magn Reson Imaging* 1999;9:53-60.
- Kono K, Inoue Y, Nakayama K, *et al.* The role of diffusion-weighted imaging in patients with brain tumors. *AJNR Am J Neuroradiol* 2001;22:1081-1088.
- Lev MH, Hochberg F. Perfusion magnetic resonance imaging to assess brain tumor responses to new therapies. *Cancer Control* 1998;5:115-123.

16. Principi M, Italiani M, Guiducci A, *et al.* Perfusion MRI in the evaluation of the relationship between tumour growth, necrosis, and angiogenesis in glioblastomas and grade 1 meningiomas. *Neuroradiology* 2003;45:205–211.
17. Cha S, Johnson G, Wadghiri YZ, *et al.* Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology. *Magn Reson Med* 2003;49:848–855.
18. WHO. Handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
19. Macdonald DR, Cascino TL, Schold SC Jr., *et al.* Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 1990;8:1277–1280.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;53:457–481.
21. Cox DR. Regression models and life-tables. *J R Stat Soc Ser B Stat Methodol* 1972;34:187–220.
22. Perry JR, Cairncross JG. Glioma therapies: How to tell which work? *J Clin Oncol* 2003;21:3547–3549.
23. Wong ET, Hess KR, Gleason MJ, *et al.* Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. *J Clin Oncol* 1999;17:2572.
24. Muti M, Aprile I, Principi M, *et al.* Study on the variations of the apparent diffusion coefficient in areas of solid tumor in high grade gliomas. *Magn Reson Imaging* 2002;20:635–641.
25. Moffat BA, Chenevert TL, Lawrence TS, *et al.* Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. *Proc Natl Acad Sci USA* 2005;102:5524–5529.